New drug for recently diagnosed type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 8 and 45 years old.
- Diagnosed with type 1 diabetes within the last 100 days.
- Must test positive for at least one diabetes-related antibody.
- Must have a certain level of C-peptide (a sign your body still makes some insulin).
- Weigh at least 35 kg (77 lbs) if 18 or older, or be within healthy weight percentiles for your age if under 18.
- Agree to avoid certain vaccines (except flu and COVID-19) during the study and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This early-stage trial is testing a new approach to slow or stop the loss of insulin-making cells in people who were recently diagnosed with type 1 diabetes. It uses a medicine called teplizumab to adjust the immune system, and the goal is to help you keep making your own insulin for as long as possible.
This study tests whether combining a shingles vaccine (Shingrix) with a diabetes medicine (semaglutide) can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may slow the progression of the disease and reduce insulin needs.
This trial tests an investigational gene therapy that may help people with type 1 diabetes produce some insulin on their own, potentially reducing the amount of insulin they need. It is an early-stage study, so participants will be closely monitored for safety and any changes in their diabetes control.
This study tests a new gene therapy (VV-14300) that aims to help people with type 1 diabetes make insulin again. It might improve blood sugar control and reduce the need for insulin.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.